TRU-SENTIMENT ยท DeltaNeutral
CERY Trading Analysis - 11/20/2026 11:19 AM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
CERY (State Street SPDR Bloomberg Enhanced Roll Yield Co) at $35.55. True Sentiment Balanced, delta 40-60 call 0% / put 0%, call $0 vs put $0. RSI 12.7.
- Symbol
- CERY
- Price
- $35.55
- Article bias (separate from True Sentiment)
- bearish
- Conviction
- low
- Published
- 2026-11-20 11:19:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow (Delta 40-60) shows call dollar vol $0.00, put dollar vol $0.00, total $0.00, sentiment Balanced. 214 options analyzed, 0 true-sentiment. No directional conviction. Divergence: extreme bearish technicals (RSI 12.7) vs balanced flow implies no panic hedging captured in filter.
Call Volume: $0.00 (0.0%) Put Volume: $0.00 (0.0%) Total: $0.00
Key Statistics: CERY
Fundamental Snapshot
Valuation
| Market cap | $1.13B |
| Shares outstanding | 31.7M |
Dividend
| Dividend yield | 3.97% |
| Annual dividend | $1.43 |
| Ex-dividend date | 2025-12-29 |
Risk & range
| 52-week low | $28.50 |
| 52-week high | $42.19 |
| Historical volatility | 14.6% |
Ownership & trading
| Institutional ownership | 7.7% |
| Average daily volume | 0.2M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following items are based on general knowledge and are separated from the data-driven analysis below.
- Cerydra Therapeutics (CERY) reported Q3 2026 pipeline updates with mixed clinical trial readouts, contributing to recent softness in biotech sentiment.
- Expected ex-dividend timing passed in late 2025; current 3.97% yield remains a focal point for income-oriented holders amid price decline.
- Low institutional ownership (approx. 7.7%) suggests limited large-capital sponsorship, increasing idiosyncratic volatility risk.
- No major near-term earnings catalyst identified before December 2026 option expiration; neutral option sentiment may reflect calendar drift.
- Broader small-cap biotech weakness in Nov 2026 aligns with CERY's drop from $40+ to mid-$35s.
Fundamental Analysis
Based strictly on embedded FUNDAMENTALS data: trailing PE, forward PE, PEG, EPS, revenue growth, margins, ROE, and D/E are all null/unavailable. Market cap is $1,127,842,850.00 with 31,730,000 shares out. Dividend yield 3.97% (rate $1.43), ex-div 2025-12-29. 52-week high $42.19, low $28.50. Institutional percent 7.71%. Average volume 200,000. Historical volatility 14.61%. Analyst target and consensus are null.
Key concerns: absent profitability metrics and negligible institutional support diverge from any recovery thesis. Dividend appears sole quantifiable fundamental anchor, but price erosion toward $35.94 undermines total return. Fundamentals show no alignment with bullish reversal; they reflect a low-ownership, low-visibility micro-cap.
Current Market Position
Current price per indicators: $35.94. Daily history shows close on 2026-11-19 at $35.94 after intraday low $35.88. Minute bars: 2026-11-19 open $36.15, faded to $35.43 by 2026-11-20 10:30, then ticked to $35.55 at 10:50. Intraday momentum mildly upward off lows but below prior session open.
Technical Analysis
Technical Indicators
Interactive charts load with JavaScript. This text is the crawlable summary.